Immune Design, Merck deal

Immune and Merck partnered to evaluate Merck’s melanoma drug Keytruda pembrolizumab with Immune’s LV305 for non-Hodgkin’s lymphoma (NHL) and G100 for melanoma in Phase I trials. Immune will sponsor the trials, and Merck will provide Keytruda. Immune said it expects the LV305 trial to begin this quarter, and the G100 trial to begin this half. ...